Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
83 hedge funds and large institutions have $100M invested in Navidea Biopharmaceuticals Inc. in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 26 increasing their positions, 20 reducing their positions, and 10 closing their positions.
30% more capital invested
Capital invested by funds: $76.9M → $100M (+$23.5M)
30% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 87 → 83 (-4)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
79% less call options, than puts
Call options by funds: $2.6M | Put options by funds: $12.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$10.4M |
| 2 |
PM
Platinum Management
New York
|
+$7.01M |
| 3 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
+$4.74M |
| 4 |
IG
ING Group
Amsterdam,
Netherlands
|
+$2.28M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$1.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
-$1.64M |
| 2 |
DA
DSC Advisors
Chicago,
Illinois
|
-$1.03M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$310K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$234K |
| 5 |
BL
Bolton LP
Greenwich,
Connecticut
|
-$160K |
NAVB Hedge Fund Activity: Q1 2014 in Review
83 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2014, worth a combined $100M — up 30% from $76.9M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of NAVB and 6 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 26 added.
The largest buyer was Susquehanna International Group, adding an estimated $10.4M. The largest seller was Catalyst Capital Advisors, exiting entirely with an estimated $1.64M sold.
- 83 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2014, down from 87 in Q4 2013.
- Funds reported $100M of Navidea Biopharmaceuticals Inc. stock for Q1 2014, up 30% quarter-over-quarter.
- 6 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2014 and 10 closed out, a net change of -4 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2014 was Susquehanna International Group, an estimated $10.4M added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q1 2014 was Catalyst Capital Advisors, an estimated $1.64M sold.
Based on aggregated 13F filings for Q1 2014.